The enhancing role of complement in human immunodeficiency virus infection: Soluble recombinant CR1 (CD35) inhibits complement-mediated enhancement of infection of a CD4-positive T-cell line with human immunodeficiency virus-1

Scandinavian Journal of Immunology

Volumn 51, Issue 5, 2000, Pages 526-529

  Delibrias, C C ^a   Fischer, E M ^a   Kazatchkine, Michel D ^a,b  

^a INSERM   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3B RECEPTOR;

ARTICLE; COMPLEMENT ACTIVATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPSONIZATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

CD4-POSITIVE T-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; HIV-1; HUMANS; RECEPTORS, COMPLEMENT 3B; SOLUBILITY; TUMOR CELLS, CULTURED;

EID: 0034020134     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2000.00715.x     Document Type: Article

References (20)

1. 1 Speth C, Kacani L, Dierich MP. Complement receptors in HIV infection. Immunol Rev 1997;159:49-67.
2. 2 Montefiori DC. Role of complement and Fc receptors in the pathogenesisof HIV-1 infection. Springer Semin Immunopathol 1997;18:371-90.
3. 3 Boyer V, Desgranges C, Trabaud MA, Fischer E, Kazatchkine MD. Complement mediates HIV-1 infection of a human T-cell line in a CD4-and antibody-independent fashion. J Exp Med 1991;173: 1151-8.
4. 4 Gras GS, Richard Y, Roques P, Olivier R, Dormont D. Complement and virus specific antibody-dependent infection of normal B lymphocytes by human immunodeficiency virus type 1. Blood 1993;81: 1808-18.
5. 5 Delibrias CC, Kazatchkine MD, Fischer E. Evidence for the role of CR1 (CD35) and CR2 (CD21) in facilitating infection of human T cells with opsonized HIV. Scand J Immunol 1993;38:183-9.
6. 6 Thieblemont N, Haeffner-Cavaillon N, Ledur A, L'Age-Stehr J, Ziegler-Hietbrock H, Kazatchkine M. CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4. Clin Exp Immunol 1993;92:106-13.
7. 7 Robinson WE, Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988;i:790-4.
8. 8 Montefiori DC, Stewart K, Ahearn JM, Zhou J, Zhou J. Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21). J Virol 1993;67:2699-706.
9. 9 Ebenbichler CF, Thielens NL, Vornhagen R, Marshang P, Arlaud GJ, Dierich MP. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991;174:1417-24.
10. 10 Tacnet-Delorme P, Boyer V, Thielens MM et al.. In vitro analysis of complement-dependent HIV-1 cell infection using a model system. J Immunol 1999;162:4088-93.
11. 11 Haurum JS, Thiel S, Jones IM, Fischer PB, Laursen SB, Jensenius JC. Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS 1993;7:1307-13.
12. 12 Weisman HF, Bartow T, Leppo MK et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249:146-51.
13. 13 Iida K, Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med 1981;153:1138-49.
14. 14 Medof ME, Iida K, Mold C, Nussenzweig V. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 1982;156:1739-54.
15. 15 Dierich MP, Ebenbichler CF, Marschang P, Füst G, Thielens NM, Arlaud GJ. HIV and human complement: Mechanisms of interaction and biological implication. Immunol Today 1993;14: 435-40.
16. 16 Mouhoub A, Thieblemont N, Delibrias C, Fischer E, Kazatchkine MD. Enhancing role of and complement in HIV infection. Clin Exp Immunol 1994;97:9-11.
17. 17 Senaldi G, Peakman M, McManus T, Davies ET, Tee DE, Vergani D. Activation of the complement system in human immunodeficiency infection: Relevance of the classical pathway to pathogenesis and disease severity. J Infect Dis 1990;162:1227-32.
18. 18 Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C3dg/EBV receptor CD21) on normal human peripheral blood human T lymphocytes. J Immunol 1991;146:865-9.
19. 19 June RA, Landay AL, Stefanik KTFL, Spear GT. Phenotypic analysis of complement receptor 2+ T lymphocytes: Reduced expression on CD4+ cells in HIV-infected persons. Immunology 1992;75:59-65.
20. 20 Kalli KR, Hsu P, Fearon DT. Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol 1994; 15:417-31.